Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Inovio Stock Is Jumping Today

By Keith Speights - Nov 27, 2020 at 11:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No news was still good news for some investors.

What happened

Shares of Inovio Pharmaceuticals ( INO 7.05% ) were jumping 10.5% as of 11:07 a.m. EST on Friday. The biotech didn't announce any new developments. But Inovio's gain likely reflected some investors' continued optimism as the company now moves ahead with a phase 2 study of COVID-19 vaccine candidate INO-4800.

So what

Investors usually shouldn't place much emphasis on big gains (or losses, for that matter) on no news the Friday after Thanksgiving. Such moves often are only noise on a historically low-volume trading day. Instead of temporary price swings, what really matters are the company's growth prospects.

Physician holding syringe with a needle and a vaccine bottle

Image source: Getty Images.

Inovio's growth prospects don't depend on just one pipeline candidate. But investors' attention is currently focused heavily on INO-4800. The experimental vaccine's results from phase 2 testing will be extremely important for the biotech stock

Other key programs to watch with Inovio include VGX-3100, which is being evaluated in a late-stage study for treating pre-cancerous cervical dysplasia. INO-5401 appears to have potential in treating glioblastoma muliforme, an aggressive type of brain cancer. The company also recently announced the dosing of the first patient in a phase 1/2 study of INO-3107 in treating recurrent respiratory papillomatosis (RRP), a rare disease where noncancerous tumor growths obstruct airways.

Now what

Inovio is working to resolve remaining questions from the Food and Drug Administration about the Cellectra 2000 device used to deliver INO-4800. Settling these questions will be needed before the company can begin a phase 3 study of INO-4800. Positive phase 2 results will also be necessary to advance the experimental COVID-19 vaccine into late-stage testing.

The biotech should have another major catalyst coming next year. Inovio expects to announce results from its Reveal-1 late-stage study of VGX-3100 in the first half of 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$6.53 (7.05%) $0.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.